Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources

Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources

L-tryptophan metabolism is involved in the regulation of many important physiological processes, such as, immune response, inflammation, and neuronal function. Indoleamine 2, 3-dioxygenase 1 (IDO1) is a key enzyme that catalyzes the first rate-limiting step of tryptophan conversion to kynurenine. Th...

Full description

Bibliographic Details
Main Authors:	Ying Tan, Miaomiao Liu, Ming Li, Yujuan Chen, Meng Ren
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Pharmacology
Subjects:	indoleamine 2, 3-dioxygenase 1 tryptophan kynurenine IDO1 inhibitors natural compounds
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1046818/full

Similar Items

The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01)

Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity
by: Mincheol Kwon, et al.
Published: (2019-01-01)

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)

Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
by: Nastran Hashemzadeh, et al.
Published: (2019-01-01)

Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase 1 Influenced the Age Onset of Parkinson's Disease
by: Nóra Török, et al.
Published: (2022-09-01)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
by: Tingming Cao, et al.
Published: (2022-01-01)

Significance of Indoleamine 2,3-Dioxygenase Expression in the Immunological Response of Kidney Graft Recipients
by: Krzysztof Wiśnicki, et al.
Published: (2022-09-01)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
by: Eleonora Panfili, et al.
Published: (2023-04-01)

IDO/kynurenine pathway in cancer: possible therapeutic approaches
by: Eslam E. Abd El-Fattah
Published: (2022-08-01)

Indoleamine-2,3-Dioxygenase 1 Deficiency Suppresses Seizures in Epilepsy
by: Ning Deng, et al.
Published: (2021-02-01)

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past
by: Yu Yao, et al.
Published: (2021-02-01)

IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01)

Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
by: Dong-Ho Lee, et al.
Published: (2017-11-01)

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
by: Peng X, et al.
Published: (2022-08-01)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
by: Asha Nayak-Kapoor, et al.
Published: (2018-06-01)

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
by: Yvonne Grobben, et al.
Published: (2021-01-01)

<i>Indoleamine 2,3-Dioxygenase 2</i> Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation
by: Kento Fujii, et al.
Published: (2020-08-01)

Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation–Cancer Interface
by: Trevor W. Stone, et al.
Published: (2023-05-01)

Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice
by: Maria J. Forteza, et al.
Published: (2018-05-01)

Comprehensive behavioral analysis of indoleamine 2,3‐dioxygenase knockout mice
by: Nao Hirata, et al.
Published: (2018-09-01)

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer
by: Yinnan Meng, et al.
Published: (2021-01-01)

Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model
by: Ewelina Rojewska, et al.
Published: (2018-07-01)

The 14kDa Protein Molecule Isolated from Garlic Suppresses Indoleamine 2, 3-Dioxygenase Metabolites in Mononuclear Cells In vitro
by: Nikoo Shohreh, et al.
Published: (2008-12-01)

Involvement of Kynurenine Pathway in Hepatocellular Carcinoma
by: Shivani Krishnamurthy, et al.
Published: (2021-10-01)

Indoleamine 2,3 Dioxygenase 1—The Potential Link between the Innate Immunity and the Ischemia-Reperfusion-Induced Acute Kidney Injury?
by: Anna Krupa, et al.
Published: (2022-05-01)

Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory Study
by: Frederike T. Fellendorf, et al.
Published: (2022-04-01)

Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents
by: Hui Wen, et al.
Published: (2019-06-01)

Indoleamine 2,3-dioxygenase expression in patients with allergic rhinitis: a case-control study
by: Luukkainen Annika, et al.
Published: (2011-12-01)

Indoleamine-2,3-Dioxygenase as a Perioperative Marker of the Immune System
by: Corina Bello, et al.
Published: (2021-11-01)

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
by: Jacques C. Mbongue, et al.
Published: (2015-09-01)

Lipopolysaccharide-Induced Delirium-like Behaviour in a Rat Model of Chronic Cerebral Hypoperfusion Is Associated with Increased Indoleamine 2,3-Dioxygenase Expression and Endotoxin Tolerance
by: Hui Phing Ang, et al.
Published: (2023-07-01)

Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
by: Karl Savonije, et al.
Published: (2023-05-01)

Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy
by: Daojing Yan, et al.
Published: (2022-04-01)

Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression
by: Irina Banzola, et al.
Published: (2018-05-01)

On the nonredundant roles of TDO2 and IDO1
by: Paolo ePuccetti
Published: (2014-10-01)

Systemic tryptophan homeostasis
by: Simon Klaessens, et al.
Published: (2022-09-01)

IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression
by: Hanako Ohmatsu, et al.
Published: (2017-02-01)

Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors
by: Chuan Zhou, et al.
Published: (2020-03-01)